OYSTER POINT PHARMA, INC. (OYST) News
Filter OYST News Items
OYST News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OYST News Highlights
- OYST's 30 day story count now stands at 2.
- Over the past 21 days, the trend for OYST's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest OYST News From Around the Web
Below are the latest news stories about OYSTER POINT PHARMA INC that investors may wish to consider to help them evaluate OYST as an investment opportunity.
Viatris completes 2 key acquisitions in vision careThe two companies will be combined into a vision-care division of the Canonsburg pharmaceutical company. |
The 7 Best Crypto and Stocks to Buy as Christmas Gifts This YearThese stocks to buy as Christmas gifts provide a number of reasons for investors to rejoice this holiday season. |
The 7 Hottest Healthcare Stocks to Own for 2023 and BeyondAs their respective catalysts (namely new treatments/products) continue to play out, each one of these seven hottest healthcare stocks has a strong chance of making another significant move higher in 2023, and in the years ahead. |
Oyster Point Pharma: Interesting Opportunity To Acquire Undervalued CVR (NASDAQ:OYST)Oyster Point Pharma is being acquired by Viatris. Tender offer includes a contingent value right that''s based on full-year 2022 metrics. Read more on OYST here. |
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common st |
7 Cheap Large-Cap Stocks to Buy Before They Surge HigherEven as they've delivered a solid performance so far this year, these seven cheap large-cap stocks to buy are still worth a look. |
Viatris And Oyster Point – Mylan All Over Again? (NASDAQ:OYST)VTRS agreed to acquire OYST and Famy Life Sciences for combined $700 million to $750 million. OYST shareholders receive $11 plus a CVR (potentially worth $1-$2) per share. |
Was anything negative for Oyster Point Pharma Inc. (OYST) stock last session?The share price of Oyster Point Pharma Inc. (NASDAQ:OYST) fell to $11.09 per share on Monday from $11.18. While Oyster Point Pharma Inc. has underperformed by -0.81%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OYST fell by -11.49%, with highs and lows ranging from $19.98 […] |
INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Oyster Point Pharma, Inc. - OYSTNEW YORK, Nov. 14, 2022 /PRNewswire/-- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at… |
Oyster Point Pharma GAAP EPS of -$1.37 misses by $0.11, revenue of $5.59M misses by $8.72MOyster Point Pharma press release (OYST): Q3 GAAP EPS of -$1.37 misses by $0.11.Revenue of $5.59M (-68.8% Y/Y) misses by $8.72M. |